Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Findings from C.A. Presant et al in breast cancer reported
January 15th, 2008
"The frequency of aromatase inhibitor (Al)-associated arthralgia and/or bone pain in clinical practice is not known. Fifty-six consecutive patients with breast cancer not on clinical trials who were receiving Als in a clinical practice were interviewed regarding occurrence of worsening or new arthralgia and/or bone pain after starting Al therapy," scientists writing in the journal Clinical Breast Cancer report. "The occurrence, character, severity, and resolution of pain were evaluated. Arthralgia and/or bone pain was reported in 61% of patients. It was severe in 30%, continuous in 41%, central in 50%, peripheral in 79%, and resulted in discontinuation of the...
Source: Cancer Weekly (2008-01-15)
|
